Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206219 | 1.00 | BCHE (0.55) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL7202284 | 0.99 | HDAC3 (0.54) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL7206186 | 0.96 | HDAC3 (0.51) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL7206336 | 0.91 | HDAC3 (0.53) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL8525848 | 0.90 | HDAC3 (0.56) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL8021840 | 0.88 | HDAC3 (0.55) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL7973240 | 0.86 | HDAC1 (0.53) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL7983340 | 0.86 | HDAC1 (0.53) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL6378615 | 0.85 | HDAC1 (0.52) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL19615968 | 0.84 | HDAC3 (0.51) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229037-A1 | Novel cationic amphiphiles | MASSING ULRICH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1261620-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | Roche Diagnostics Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001057064-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | ROCHE DIAGNOSTICS CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229037-A1 | Novel cationic amphiphiles | ABHD16A, APMAP, ABCB4 | BCHE 3299/4885ACHE 4751/4885HDAC3 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.